Dendreon Corporation (NASDAQ:DNDN) tumbled around 16% in previous session, as triggering a trading bring to a close, following the biotechnology firm announced lower  than anticipated sales for its centerpiece cancer drug, Provenge. Dendreon’s stocks trading were stop and constraints on short sales for the stock were triggered in an attempt to maintain shares from drop…